John G Ullman & Associates Inc. Has $328,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

John G Ullman & Associates Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,478 shares of the biopharmaceutical company’s stock after purchasing an additional 700 shares during the period. John G Ullman & Associates Inc.’s holdings in Gilead Sciences were worth $328,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Hemenway Trust Co LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $487,000. SPC Financial Inc. lifted its holdings in Gilead Sciences by 10.5% in the first quarter. SPC Financial Inc. now owns 4,212 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 400 shares during the period. Noesis Capital Mangement Corp lifted its holdings in Gilead Sciences by 4.9% in the first quarter. Noesis Capital Mangement Corp now owns 111,668 shares of the biopharmaceutical company’s stock valued at $8,180,000 after buying an additional 5,223 shares during the period. Affinity Investment Advisors LLC lifted its holdings in Gilead Sciences by 13.9% in the first quarter. Affinity Investment Advisors LLC now owns 21,586 shares of the biopharmaceutical company’s stock valued at $1,581,000 after buying an additional 2,640 shares during the period. Finally, Catalina Capital Group LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $204,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

GILD stock traded up $0.62 during trading hours on Friday, reaching $70.59. The stock had a trading volume of 448,451 shares, compared to its average volume of 7,463,721. The stock has a market capitalization of $87.94 billion, a PE ratio of 196.03, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The stock has a 50-day simple moving average of $66.32 and a 200 day simple moving average of $71.87. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.37 EPS. Analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.36%. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday. Morgan Stanley lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $84.00.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.